Miran Kim, PhD
Miran Kim, PhD
Miran Kim, PhD
PhD, KAIST (Korea Advanced Institute of Science and Technology), Korea
MS, Seoul National University, College of Pharmacy, Seoul, Korea
Wnt signaling in hepatic oncogenesis; T-cell factor isofomrs on liver cancer; signaling pathways in liver regeneration
Miran Kim, PhD, is a tumor cell biologist and assistant professor in the Department of Internal Medicine, Rush University Medical Center. She received a PhD in Life Science from KAIST in South Korea and trained at the Salk Institute in San Diego, California of Sheffield in UK as a postdoctoral research fellow. Her research has been focused on the molecular and cellular mechanisms of liver cancer for over 15 years. Over a decade of her work at Brown School/Rhode Island Hospital broadened the knowledge of T-cell factor-4 (TC-4) splicing isoforms in hepatocellular carcinoma (HCC) and found evidence that only a certain subset of these proteins contributed to hepatocyte transformation and malignant phenotype. Her current research interests include the relationship between loco-regional therapy and TCF-4 in HCC; tumor microenvironment and tumor-associated immune cells.
RTSC-SAA award, Rush University Medical Center (2018)
Developmental Research Award, Department of Medicine, Rhode Island Hospital, Providence, RI (2009-2011)
Wellcome Trust Research Fellowship, Institute of Molecular Physiology, University of Sheffield, Sheffield, UK (2001-2003)
AstraZeneca Research Fellowship, Institute of Molecular Physiology, University of Sheffield, Sheffield, UK (1999-2000)